Trial Profile

Double-blind, placebo-controlled, dose-escalating phase 1 trial of LCB10 0200 (GT-1) in healthy volunteers

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 04 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LCB10-0200 (Primary)
Indications Gram-negative infections
Focus Adverse reactions

Most Recent Events

30 May 2018 According to a Geom Therapeutics media release, this trial is expected to begin in 2H of 2018.
30 May 2018 According to a Geom Therapeutics media release, company plans to submit an IND to the FDA in 2H 2018.
27 Sep 2017 According to a Geom Therapeutics media release, the company is planning to initiate Phase 1 studies in 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com